First Time Loading...

Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211

Watchlist Manager
Tibet Rhodiola Pharmaceutical Holding Co Logo
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Watchlist
Price: 39.15 CNY 1.16% Market Closed
Updated: May 14, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

4.6B
-3%
Assets
Growth Rates:
1 Year
+12%
3 Years
+56%
5 Years
+81%
7 Years
+100%
10 Years
+302%
1.2B
-5%
Liabilities
Growth Rates:
1 Year
+14%
3 Years
+238%
5 Years
+344%
7 Years
-24%
10 Years
+66%
3.3B
-2%
Equity
Growth Rates:
1 Year
+11%
3 Years
+30%
5 Years
+48%
7 Years
+406%
10 Years
+755%

Balance Sheet Decomposition
Tibet Rhodiola Pharmaceutical Holding Co

4.6B
Assets
1.2B
Liabilities
4.6B
Assets
1.2B
Liabilities
Current Assets 3.4B
Cash & Short-Term Investments 1.2B
Receivables 902.8m
Other Current Assets 1.3B
Non-Current Assets 1.2B
Long-Term Investments 250.7m
PP&E 602.4m
Intangibles 212.7m
Other Non-Current Assets 118.8m
Current Liabilities 1.2B
Accounts Payable 38.9m
Accrued Liabilities 93.2m
Short-Term Debt 499.5m
Other Current Liabilities 552.9m
Non-Current Liabilities 58.3m
Long-Term Debt 1.1m
Other Non-Current Liabilities 57.2m

Balance Sheet
Tibet Rhodiola Pharmaceutical Holding Co

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
300
319
373
315
529
737
768
756
929
686
Cash
2
0
0
0
0
0
0
756
927
666
Cash Equivalents
298
319
373
315
529
737
768
0
2
21
Short-Term Investments
0
0
0
0
0
90
15
538
792
515
Total Receivables
171
37
105
405
494
424
493
727
669
903
Accounts Receivables
125
19
61
335
379
307
333
471
447
651
Other Receivables
46
18
44
70
115
117
160
256
222
252
Inventory
306
126
94
87
62
75
71
137
100
111
Other Current Assets
34
2
68
5
2
15
4
23
222
1 187
Total Current Assets
811
484
642
812
1 088
1 341
1 351
2 182
2 712
3 403
PP&E Net
109
107
149
150
160
192
221
793
610
602
PP&E Gross
109
107
149
150
160
192
221
793
610
602
Accumulated Depreciation
78
83
95
104
109
120
132
138
245
409
Intangible Assets
34
33
1 333
1 198
1 131
1 089
965
456
418
204
Goodwill
9
9
9
9
9
9
9
9
9
9
Long-Term Investments
76
67
154
148
119
115
172
278
271
251
Other Long-Term Assets
8
6
6
14
25
22
227
84
81
119
Other Assets
9
9
9
9
9
9
9
9
9
9
Total Assets
1 046
N/A
706
-33%
2 291
+224%
2 330
+2%
2 532
+9%
2 767
+9%
2 944
+6%
3 803
+29%
4 100
+8%
4 587
+12%
Liabilities
Accounts Payable
97
6
580
11
9
12
8
101
42
39
Accrued Liabilities
54
71
78
28
32
41
32
60
71
93
Short-Term Debt
130
0
0
0
0
0
0
534
486
500
Current Portion of Long-Term Debt
135
45
45
0
0
0
0
2
1
1
Other Current Liabilities
190
71
902
225
220
257
293
412
426
552
Total Current Liabilities
605
192
1 605
264
261
310
333
1 110
1 026
1 184
Long-Term Debt
0
0
0
0
0
0
10
2
1
1
Deferred Income Tax
1
0
1
1
0
0
2
16
14
2
Minority Interest
10
4
2
2
5
10
12
15
19
29
Other Liabilities
26
28
27
20
14
10
11
31
28
26
Total Liabilities
642
N/A
217
-66%
1 630
+651%
287
-82%
280
-3%
330
+18%
368
+12%
1 172
+218%
1 088
-7%
1 243
+14%
Equity
Common Stock
146
146
146
180
180
177
248
248
248
248
Retained Earnings
39
123
294
464
610
856
1 086
1 169
1 455
1 773
Additional Paid In Capital
217
217
217
1 409
1 409
1 327
1 264
1 265
1 266
1 263
Other Equity
4
4
5
9
54
78
22
51
43
61
Total Equity
404
N/A
490
+21%
661
+35%
2 043
+209%
2 253
+10%
2 437
+8%
2 576
+6%
2 630
+2%
3 012
+15%
3 345
+11%
Total Liabilities & Equity
1 046
N/A
706
-33%
2 291
+224%
2 330
+2%
2 532
+9%
2 767
+9%
2 944
+6%
3 803
+29%
4 100
+8%
4 587
+12%
Shares Outstanding
Common Shares Outstanding
204
204
204
252
252
248
248
248
248
248

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.